Papadopoulos will report directly to Emergex's CEO Professor Thomas Rademacher.
In his new role Papadopoulos will use his extensive medical, regulatory and clinical development expertise to provide leadership and direction on the development of Emergex's growing pipeline of vaccines.
Papadopoulos joins Emergex from Sanofi, the global pharmaceutical company, where he was most recently Associate vice president, senior director and Clinical Franchise Leader of Global Clinical Sciences since 2015. During his time at Sanofi Dr. Papadopoulos played a critical role in the development of Dengvaxia, the first vaccine approved for Dengue fever.
Prior to joining Sanofi, Dr. Papadopoulos worked at Novartis as Medical Affairs director and Senior Global Clinical Research Physician as well as Lead Head of CLS and Senior director of Clinical Development. During his time at Novartis, he contributed to the successful development and approval of the breakthrough Bexsero Meningitis B vaccine.
Papadopoulos originally trained as a general practitioner in Greece and specialized as a clinical bio-pathology consultant.
Emergex Vaccines Holding, a UK-based biotechnology company headquartered in Oxford, is developing a new approach to vaccine development in order to address some of the world's most immediate health threats including Flaviviruses, such as Dengue Fever and Zika as well as Filoviruses, such as Ebola and Marburg viruses, and seasonal and pandemic influenza.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV